Contents

Preface *XXI*

List of Contributors *XXIII*

Abbreviations *XXVII*

Colour Plates *XXXVII*

Part I Fundamentals of Cellular and Molecular Biology

1 The Cell as the Basic Unit of Life *3*
M. Wink

2 Structure and Function of Cellular Macromolecules *7*
M. Wink
2.1 Introduction *7*
2.2 Structure and Function of Sugars *9*
2.3 Structure of Membrane Lipids *12*
2.4 Structure and Function of Proteins *17*
2.5 Structure of Nucleotides and Nucleic Acids (DNA and RNA) *29*

3 Structure and Function of a Cell *39*
M. Wink
3.1 The Structure of a Eukaryotic Cell *40*
3.1.1 The Structure and Function of the Cytoplasmic Membrane *40*
3.1.1.1 Membrane Permeability *41*
3.1.1.2 Transport Processes Across Biomembranes *43*
3.1.1.3 Receptors and Signal Transduction at Biomembranes *47*
3.1.2 The Endomembrane System in a Eukaryotic Cell *52*
3.1.3 Mitochondria and Chloroplasts *55*
3.1.4 Cytoplasm *62*
3.1.5 Cytoskeleton *65*
3.1.6 Cell Walls *68*

An Introduction to Molecular Biotechnology. Edited by M. Wink

ISBN: 3-527-31412-1

3.2 The Structure of Bacteria *69*
3.3 The Structure of Viruses *70*
3.4 The Differentiation of Cells *72*

4 Biosynthesis and Function of Macromolecules (DNA, RNA, and Proteins) *77*
M. Wink
4.1 Genomes, Chromosomes, and Replication *77*
4.1.1 Genome Size *78*
4.1.2 Composition and Function of Chromosomes *83*
4.1.3 Mitosis and Meiosis *86*
4.1.4 Replication *89*
4.1.5 Mutations and Repair Mechanisms *91*
4.2 Transcription: From Gene to Protein *96*
4.3 Protein Biosynthesis (Translation) *102*

5 Distributing Proteins in the Cell (Protein Sorting) *109*
M. Wink
5.1 Import and Export of Proteins via the Nuclear Pore *111*
5.2 Import of Proteins in Mitochondria and Chloroplasts *112*
5.3 Protein Transport in the Endoplasmic Reticulum *114*
5.4 Vesicle Transport from the ER via the Golgi Apparatus to the Cytoplasmic Membrane *116*

6 Diversity of Organisms *121*
M. Wink
6.1 Prokaryotes *121*
6.2 Eukaryotes *122*
Further Reading for Chapters 1–6 *126*

Part II Standard Methods in Molecular Biotechnology

7 Isolation and Purification of Proteins *131*
T. Wieland, S. Lutz
7.1 Introduction *131*
7.2 Producing a Protein Extract *133*
7.3 Gel Electrophoretic Separation Methods *134*
7.3.1 Principles of Electrophoresis *134*
7.3.2 Native Gel Electrophoresis *134*
7.3.3 Discontinuous Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) *135*
7.3.4 Two-Dimensional (2D) Gel Electrophoresis, Isoelectric Focussing (IEF) *136*
7.3.5 Detecting Proteins in Gels *137*
7.4 Methods of Protein Precipitation *137*

7.5 Column Chromatography Methods *138*
7.5.1 General Principles of Separation *138*
7.5.1.1 Size Exclusion Chromatography (Gel Filtration) *139*
7.5.1.2 Hydrophobic Interaction Chromatography (HIC) *141*
7.5.1.3 Ion Exchange Chromatography *141*
7.5.1.4 Hydroxyapatite Chromatography *143*
7.5.2 Group-specific Separation Techniques *143*
7.5.2.1 Chromatography on Protein A or Protein G *143*
7.5.2.2 Chromatography on Cibacron Blue (Blue Gel) *144*
7.5.2.3 Chromatography on Lectins *144*
7.5.2.4 Chromatography on Heparin *145*
7.5.3 Purification of Recombinant Fusion Proteins *145*
7.5.3.1 Chromatography on Chelating Agents *145*
7.5.3.2 Chromatography on Glutathion-Matrices *146*
7.6 Examples *146*
7.6.1 Example 1: Purification of Nucleoside Diphosphate Kinase from the Cytosol of Bovine Retina Rod Cells *146*
7.6.2 Example 2: Purification of Recombinant His_6-RGS16 after Expression in *E. coli* *148*
Further Reading *149*

8 Peptide and Protein Analysis with Electrospray Tandem Mass Spectrometry *151*
A. Schlosser, W. D. Lehmann
8.1 Introduction *151*
8.2 Principles of Mass Spectrometry *151*
8.3 Mass Precision, Resolution, and Isotope Distribution *152*
8.4 Principles of Electrospray Ionization *153*
8.5 Tandem Mass Spectrometers *154*
8.5.1 Mass Analyzers *154*
8.5.2 Triple Quadrupole *155*
8.5.3 Ion Trap (Paul Trap) *156*
8.5.4 Q-TOF *156*
8.5.5 Q-FT-ICR *157*
8.6 Peptide Sequencing with MS/MS *157*
8.7 Identifying Proteins with MS/MS-Data and Protein Databases *158*
8.7.1 Databank Search with Sequence Data *158*
8.7.2 Databank Search with MS/MS Raw Data *159*
8.8 Determining Protein Molecular Mass *160*
8.9 Analysis of Covalent Protein Modification *162*
Further Reading *164*

9 Isolation of DNA and RNA *165*
H. Weiher, R. Zwacka, I. Herr
9.1 Introduction *165*

9.2 DNA Isolation *166*
9.3 RNA Isolation *168*
9.3.1 Enrichment of Messenger RNA (mRNA) *169*
References *169*

10 Chromatography and Electrophoresis of Nucleic Acids *171*
H. Weiher, R. Zwacka, I. Herr
10.1 Introduction *171*
10.2 Chromatographic Separation of Nucleic Acids *171*
10.3 Electrophoresis *172*
10.3.1 Agarose Gel Electrophoresis: Submarine Electrophoresis *173*
10.3.2 Pulsed Field Agarose Gel Electrophoresis *174*
10.3.3 Polyacrylamide Gel Electrophoresis (PAGE) *174*
Further Reading *174*

11 Hybridization of Nucleic Acids *175*
H. Weiher, R. Zwacka, I. Herr
11.1 The Significance of Base Pairing *175*
11.2 Experimental Hybridization, Kinetic, and Thermodynamic Control *176*
11.3 Analytical Techniques *176*
11.3.1 Clone Detection, Southern Blotting, Northern Blotting, and Gene Diagnosis *176*
11.3.2 Expression Screening *178*
11.3.3 *In Situ* Hybridization *179*
Further Reading *180*

12 The Use of Enzymes in the Modification of Nucleic Acids *181*
I. Herr, H. Weiher, R. Zwacka
12.1 Restriction Enzymes (Restriction Endonucleases) *181*
12.2 Ligases *183*
12.3 Methylases *184*
12.4 DNA Polymerases *185*
12.5 Nucleases *186*
12.6 T4 Polynucleotide Kinase *187*
12.7 Calf Intestinal Phosphatase *187*
Further Reading *187*

13 Polymerase Chain Reaction (PCR) *189*
A. Mohr, H. Weiher, I. Herr, R. Zwacka
13.1 Introduction *189*
13.2 Techniques *190*
13.2.1 Standard PCR *190*
13.2.2 RT-PCR *192*
13.2.3 Quantitative/Real Time PCR *193*
13.2.4 Rapid Amplification of cDNA Ends (RACE) *194*

13.3 Areas of Application *195*
13.3.1 Genome Analysis *195*
13.3.2 Cloning Technology *195*
13.3.3 Expression Studies *196*
Further Reading *196*

14 DNA Sequencing *197*
R. Zwacka, A. Mohr, I. Herr, H. Weiher
14.1 Introduction *197*
14.2 DNA Sequencing Methods *198*
14.2.1 Chemical Sequencing Method (Maxam-Gilbert Method) *198*
14.2.2 Enzymatic Sequencing (Sanger-Coulson Method) *198*
14.3 Strategies for Sequencing the Human Genome *200*
14.4 The Practical Significance of DNA Sequencing *201*
Further Reading *201*

15 Cloning Procedures *203*
T. Wieland, S. Lutz
15.1 Introduction *203*
15.2 The Production of Recombinant Vectors *204*
15.2.1 The Insert *204*
15.2.2 The Vector *208*
15.2.3 Essential Components of Vectors *208*
15.2.3.1 The Bacterial Origin of Replication (*ori*) *208*
15.2.3.2 Antibiotic Resistance *209*
15.2.3.3 Polylinkers *209*
15.2.4 Cloning Using Recombination Systems *209*
15.2.5 Further Components of Vectors for Prokaryotic Expression Systems *211*
15.2.5.1 The Promoter *211*
15.2.5.2 The Ribosome Binding Site *211*
15.2.5.3 The Termination Sequence *212*
15.2.5.4 The Fusion Sequence *212*
15.2.6 Further Components of Eukaryotic Expression Vectors *213*
15.2.6.1 Eukaryotic Expression Vectors: Yeast *213*
15.2.6.2 Eukaryotic Expression Vectors for Mammal Cells *214*
15.2.6.3 Viral Expression Systems for Mammalian Cells *218*
15.2.7 Nonviral Introduction of Heterologous DNA to Host Organisms (Transformation, Transfection) *220*
15.2.7.1 Transformation of Prokaryotes *220*
15.2.7.2 Transformation of Yeast Cells *221*
15.2.7.3 Transfection of Mammal Cells *221*
Further Reading *222*

16 Expression of Recombinant Proteins *223*
T. Wieland, S. Lutz
16.1 Introduction *223*
16.2 Expression of Recombinant Proteins in Host Organisms *224*
16.2.1 Expression in *E. coli* *228*
16.2.2 Expression in Yeasts *230*
16.2.3 Expression in Insect Cells *232*
16.2.3.1 Expression Based on Recombinant Baculoviruses *232*
16.2.3.2 Expression of Proteins in Stably Transfected Insect Cells *234*
16.2.4 Expression of Proteins in Mammalian Cells *235*
16.3 Expression in Cell-Free Systems *236*
16.3.1 Expression of Proteins in Reticulocyte Lysates *237*
16.3.2 Protein Expression Using *E. coli* Extracts *237*
Further Reading *238*

17 The Patch Clamp Method *239*
R. Kraft, S. Patt
17.1 Biological Membranes and Ion Channels *239*
17.2 Physical Foundations of the Patch Clamp Method *240*
17.3 Patch Clamp Configurations *241*
17.4 Heterologous Expression Systems and Section Preparations *244*
Further Reading *245*

18 Cell Cycle Analysis *247*
S. Wölfl, A. Kitanovic
18.1 Analyzing the Cell Cycle *247*
18.2 Experimental Analysis of the Cell Cycle *249*
18.2.1 Preparing Synchronized Cell Cultures of *Saccharomyces cerevisiae* *250*
18.2.2 Centrifugal Elutriation *250*
18.2.3 Cell Cycle Arrest Using the Alpha Factor *251*
18.2.4 The Identification of Cell Cycle Stages *252*
18.2.4.1 The Budding Index *252*
18.2.4.2 Fluorescent Staining of the Nucleus *252*
Further Reading *256*

19 Techniques in Microscopy *257*
G. Fricker
19.1 Light Microscopy *257*
19.2 Phase Contrast Light Microscopy *257*
19.3 Darkfield Microscopy *259*
19.4 Polarization and Interference Microscopy *259*
19.5 Fluorescence Microscopy *260*
19.6 Confocal Fluorescence Microscopy *261*
19.7 Electron Microscopy *262*
Further Reading *264*

20 Laser Applications *265*
M. Vogel, R. Fink
20.1 Principles of Laser Technology *265*
20.2 Properties of Laser Radiation *267*
20.3 Types of Lasers and Their Setups *268*
20.4 Applications *269*
20.4.1 Confocal and Multiphoton Microscopy *269*
20.4.2 Optical Tweezers *270*
20.4.3 Laser Microdissection *270*
Further Reading *270*

Part III Key Topics

21 Genomics *273*
M. Frohme, St. Wiemann
21.1 Introduction *273*
21.2 Technological Developments in Sequencing *276*
21.2.1 Sequencing Technology *276*
21.2.2 Biochemistry *276*
21.2.3 Equipment *279*
21.2.4 Software and Informatics for Sequencing *280*
21.3 Genome Sequencing *281*
21.3.1 Mapping *281*
21.3.1.1 Restriction Mapping and Restriction Fingerprinting *284*
21.3.1.2 BAC-End Sequencing *285*
21.3.1.3 Genetic Mapping *285*
21.3.1.4 Radiation Hybrid Mapping *288*
21.3.1.5 HAPPY Mapping *289*
21.3.1.6 Mapping by Hybridization *290*
21.3.1.7 STS, ESTs, SNPs, and Sequencing Length Polymorphisms (AFLPs, RAPD) *292*
21.3.1.8 FISH, Fibre Fish, Optical Mapping, and CGH *295*
21.3.2 Time-line of Genome Sequencing *296*
21.3.3 Genome Sequencing Strategies *296*
21.3.3.1 Conventional Approach: Random Shotgun Strategy *296*
21.3.3.2 The Whole-Genome Shotgun Strategy *300*
21.3.3.3 Sequencing of the Human Genome *302*
21.3.4 Outlook for Genome Sequencing *303*
21.4 cDNA Projects *304*
21.4.1 cDNAs Represent the Cell's mRNA *304*
21.4.2 Production of cDNA Libraries *306*
21.4.3 EST-Projects for Gene Identification *310*
21.4.3.1 What is an EST? *310*
21.4.3.2 IMAGE Consortium: CGAP *313*
21.4.3.3 UniGene *314*

21.4.4 Full-length Project for the Production of Resources for Functional Genomics *316*
Further Reading *318*

22 Functional Genomics *321*
M. Frohme, St. Wiemann
22.1 Introduction *321*
22.2 The Identification and Analysis of Individual Genes *324*
22.2.1 Positional Cloning *325*
22.2.2 Gene Trap *328*
22.2.3 DNA/RNA *In Situ* Hybridization *329*
22.2.4 Tissue Arrays *330*
22.3 The Investigation of Transcriptional Activity *331*
22.3.1 SAGE (Serial Analysis of Gene Expression) *332*
22.3.2 Subtractive Hybridization *334*
22.3.3 RNA Fingerprinting *337*
22.3.4 Array-based Techniques *340*
22.3.4.1 Macroarrays *343*
22.3.4.2 Microarrays *345*
22.3.4.3 Global and Specific Arrays *347*
22.3.5 Specificity and Sensitivity *349*
22.4 Cell-based Methods *350*
22.4.1 GFP Techniques *350*
22.4.2 Alternatives to GFP *351*
22.4.3 Fluorescence Resonance Energy Transfer (FRET) *352*
22.4.4 Fluorescence Recovery After Photobleaching (FRAP) *354*
22.4.5 Cell-based Assays *355*
22.4.5.1 Assay Design *356*
22.4.5.2 Pipetting Systems *357*
22.4.5.3 Reading and Recording of Data *358*
22.4.5.4 Data Analysis *359*
22.5 Functional Analysis of Entire Genomes *360*
22.5.1 Genotypic Screening in Yeast *360*
22.5.2 Phenotypic Screening in the Mouse *361*
Further Reading *363*

23 Protein–Protein and Protein–DNA Interaction *365*
P. Uetz, E. Pohl
23.1 Protein–Protein Interactions *366*
23.1.1 Classification and Specificity: Protein Domains *366*
23.1.2 Protein Networks and Complexes *367*
23.1.3 Structural Properties of Interacting Proteins *370*
23.1.4 Which Forces Mediate Protein–Protein Interactions? *371*
23.1.4.1 Thermodynamics *371*
23.1.4.2 Energetics *372*

23.1.5 Methods to Examine Protein–Protein Interactions *373*
23.1.6 Regulation of Protein–Protein Interactions *374*
23.1.7 Theoretical Prediction of Protein–Protein Interactions *375*
23.1.8 Biotechnological and Medical Applications of Protein–Protein Interactions *376*
23.2 Protein–DNA Interactions *378*
23.2.1 Sequence-specific DNA-binding *378*
23.2.2 Thermodynamic Considerations Regarding Protein–DNA Complexes *379*
23.2.3 Methods to Study Protein–DNA Interactions *379*
23.2.4 Medical Relevance of Protein–DNA Interactions *384*
23.2.5 Biotechnological Applications of Protein–DNA Interactions *385*
Further Reading *385*

24 Bioinformatics *387*
B. Brors, K. Fellenberg
24.1 Introduction *387*
24.2 Data Sources *388*
24.2.1 Primary Databanks: EMBL/GenBank/DDBJ, PIR, SwissProt *388*
24.2.2 Motif Databanks: BLOCKS, Prosite, PFAM, ProDom, SMART *389*
24.2.3 Molecular Structure Databanks: PDB, SCOP *389*
24.2.4 Transcriptome Databanks: SAGE, ArrayExpress, GEO *390*
24.2.5 Reference Databanks: PubMed, OMIM, GeneCards *390*
24.3 Sequence Analysis *391*
24.3.1 Kyte–Doolittle, Helical Wheel, Signal Sequence Analysis *391*
24.3.2 Pair Alignment *393*
24.3.2.1 Local/Global *394*
24.3.2.2 Optimal/Heuristic *394*
24.3.3 Alignment Statistics *394*
24.3.4 Multiple Alignment *395*
24.3.5 Phylogenetic Analysis *396*
24.4 Gene Prediction *398*
24.4.1 Neuronal Networks or Hidden Markov Models Based on Hexanucleotide Composition *399*
24.4.2 Comparison with ESTs or Other Genomes (*Fugu*, Mouse) *400*
24.5 Bioinformatics in Transcriptome and Proteome Analysis *402*
24.5.1 Pre-processing, Normalization *402*
24.5.2 Character Selection *404*
24.5.3 Similarity Measures: Euclidean Distance, Correlation, Manhattan Distance, Mahalanobis Distance, Entropy Measures *405*
24.5.4 Unsupervised Learning Procedures: Clustering, Main Component Analysis, Multidimensional Scaling, Correspondence Analysis *406*
24.5.5 Supervised Learning Procedures: Linear Discriminant Analysis, Choice Trees, Support Vector Machines, Artificial Neuronal Networks *407*

24.6 Systems Biology *408*
24.6.1 Networks: Boolean Networks and Bayesian Networks *410*
24.6.2 Deterministic Descriptions: Common and Partial Differential Equations *410*
24.6.3 Nondeterministic Description: Stochastical Simulation *411*
Further Reading *411*

25 Drug Research *413*
U. Denschle, M. Kögl, R. Tolle
25.1 Introduction *413*
25.2 Active Compounds and Their Targets *414*
25.2.1 Genomic Methods for the Identification of Targets *415*
25.2.2 Bioinformatic Identification of Targets *416*
25.2.3 Comparative Genome Analysis *417*
25.2.4 Experimental Target Identification: *In Vitro* Method *418*
25.2.5 Experimental Identification of Targets: Model Organisms *418*
25.2.6 Experimental Target Identification in Humans *419*
25.2.7 The Difference Between Target Candidates and Genuine Targets *420*
25.2.8 Biologicals *422*
25.2.9 DNA and RNA in New Therapeutic Approaches *424*
25.2.10 Patent Protection for Targets *424*
25.2.11 Compound Libraries *425*
25.2.12 High-Throughput Screening *426*
25.2.13 High Quality Paramounts in Screening Assays *430*
25.2.14 Virtual Ligand Screening *431*
25.2.15 The Activity of Agents Described in Terms of Efficiency and Potency *431*
25.2.16 Chemical Optimization of Lead Structures *432*
25.3 Pre-Clinical Pharmacology and Toxicology *432*
25.4 Clinical Development *433*
25.5 Clinical Testing *434*
Further Reading *435*

26 Drug Targeting and Prodrugs *437*
G. Fricker
26.1 Drug Targeting *437*
26.1.1 Passive Targeting by Exploiting Special Physiological Properties of the Target Tissue *438*
26.1.2 Physical Targeting *439*
26.1.3 Active Targeting *440*
26.1.4 Cellular Carrier Systems *444*
26.2 Prodrugs *445*
26.2.1 Prodrugs to Improve Drug Solubility *445*
26.2.2 Prodrugs to Increase Stability *446*

26.3 Penetration of Drugs through Biological Membranes *446*
26.4 Prodrugs to Extend Duration of Effect *448*
26.5 Prodrugs for the Targeted Release of a Drug *449*
26.6 Prodrugs to Minimize Side Effects *451*
Further Reading *451*

27 Molecular Diagnostics in Medicine *455*
S. Wölfl, R. Gessner
27.1 Uses of Molecular Diagnostics *456*
27.1.1 Introduction *456*
27.1.2 Monogenic and Polygenic Diseases *456*
27.1.3 Individual Variability in the Genome: Forensics *459*
27.1.4 Individual Variability in the Genome: HLA Typing *459*
27.1.5 Individual Variability in the Genome: Pharmacogenomics *459*
27.1.6 Individual Variability in the Genome: Susceptibility to Infectious Diseases *460*
27.1.7 Viral Diagnosis *460*
27.1.8 Microbial Diagnosis and Resistance Diagnosis *461*
27.2 Which Molecular Variations should be detected? *462*
27.2.1 Point Mutations *462*
27.2.2 Insertions and Deletions *464*
27.2.3 Nucleotide Repeats *464*
27.2.4 Deletion or Duplication of Genes *465*
27.2.5 Recombination Between Chromosomes *465*
27.2.6 Epigenic Changes *466*
27.3 Molecular Diagnostic Methods *466*
27.3.1 DNA/RNA Purification *467*
27.3.2 Determination of Known Sequence Variations *467*
27.3.2.1 Direct Length Polymorphism *467*
27.3.2.2 RFLP *467*
27.3.2.3 ACRS *469*
27.3.2.4 ARMS *469*
27.3.2.5 MS-PCR *469*
27.3.2.6 Allele-specific Hybridization *470*
27.3.2.7 LCR *470*
27.3.2.8 Minisequencing *470*
27.3.2.9 Pyrosequencing *472*
27.3.2.10 Quantitative PCR *472*
27.3.2.11 Chip Technology *473*
27.3.2.12 Production and Manufacture of Microarrays *474*
27.3.2.13 Determination of Unknown Mutations *476*
27.4 Outlook *477*
Further Reading *477*

28 Recombinant Antibodies and Phage Display *479*
S. Dübel
28.1 Introduction *479*
28.2 Why Recombinant Antibodies? *481*
28.2.1 Recombinant Antibodies are Available *In Vitro* without Immunization *481*
28.2.2 Antibodies with New Characteristics Can Be Created *482*
28.3 Obtaining Specific Recombinant Antibodies *483*
28.3.1 Preparation of the Variety of Antibody Genes *483*
28.3.2 Selection Systems for Recombinant Antibodies *485*
28.3.2.1 Transgenic Mice *485*
28.3.2.2 *In Vitro* Selection Systems *486*
28.4 Production of Recombinant Antibodies *489*
28.4.1 Recombinant Production Systems *489*
28.4.2 Purification of Recombinant Antibodies and their Fragments *491*
28.5 Formats for Recombinant Antibodies *491*
28.5.1 Monospecific Antibody Fragments *493*
28.5.1.1 Fab Fragments *493*
28.5.1.2 Fv Fragments *493*
28.5.1.3 Single Chain Antibody Fragments (scFv) *494*
28.5.1.4 Disulphide Stabilized Fv Fragments (dsFv) *494*
28.5.1.5 V_H and Camel Antibodies *495*
28.5.2 Multivalent Antibody Fragments *495*
28.5.2.1 Bifunctional Antibodies *496*
28.5.2.2 Bispecific Antibodies *496*
28.6 Applications of Recombinant Antibodies *499*
28.6.1 Clinical Applications *499*
28.6.2 Applications in Research and *In Vitro* Diagnostics *500*
28.6.2.1 Recombinant Antibodies in Laboratory Diagnostics *501*
28.6.2.2 Intracellular Antibodies *501*
28.6.2.3 Recombinant Antibodies as Binding Molecules for Arrays *501*
28.7 Outlook *502*
Further Reading *502*

29 Genetically Modified Mice (Transgenic and Knockout) and their Impact on Medicine *511*
R. Sprengel
29.1 Overview *511*
29.2 Transgenic Mice *514*
29.2.1 Retroviral Infection of the Transgenic Mouse *515*
29.2.2 Injection into the Pronucleus for the Production of Transgenic Mice *515*
29.2.3 Homologous Recombination for the Production of Transgenic Mice *517*
29.3 The Impact of Genetically Modified Mice in Biomedicine *521*
Further Reading *522*

30 Gene Therapy: Strategies and Vectors *523*
I. Herr
30.1 Introduction *523*
30.2 Principles of Somatic Gene Therapy *525*
30.3 Germ Line Therapy *527*
30.4 Setbacks in Gene Therapy *528*
30.5 Vectors for Gene Therapy *530*
30.5.1 Retroviral Vectors *531*
30.5.2 Adenoviral Vectors *535*
30.5.3 Adeno-Associated Virus (AAV) *538*
30.5.4 Other Viral Vectors *540*
30.6 Specific Expression *541*
Further Reading *542*

31 Modified DNA, PNA, and Applications in Medicine and Biotechnology *543*
N. Metzler-Nolte
31.1 Introduction *543*
31.2 Modified Nucleic Acids *544*
31.2.1 Phosphorthioate *545*
31.2.2 Methylphosphonate *547*
31.2.3 Peptide Nucleic Acids (PNA) *548*
31.3 Interactions of DNA Analogs with Complementary DNA and RNA *549*
31.3.1 Melting Temperature *549*
31.3.2 Mismatch Sensitivity *551*
31.4 Applications *552*
31.4.1 Antisense Technique *552*
31.4.2 Other Applications for PNA *554*
Further Reading *556*

32 Plant Biotechnology *557*
R. Hell, H. Hillebrand
32.1 Introduction *557*
32.1.1 The *Green* Genetic Engineering – A New Method on the Way to Traditional Goals *557*
32.1.2 Special Aspects of Plant Biotechnology *559*
32.2 Development of Transgenic Plants *559*
32.2.1 Transformation Through DNA Transfer *560*
32.2.1.1 *Agrobacterium* as a Natural Transformation System *560*
32.2.1.2 Biolistic Method: Gene Gun *563*
32.2.1.3 Other Physical Transformation Systems *565*
32.2.1.4 Plastid Transformation *565*
32.2.1.5 Viral Systems *567*
32.3 Selection of Transformed Plant Cells *568*

32.3.1 Requirements for an Optimal Selection Marker System *568*
32.3.2 Negative Selection Marker Systems *570*
32.3.3 Positive Selection Marker System *571*
32.3.4 Counter Selection *572*
32.3.5 Visual Markers *573*
32.3.6 Selection Systems Genetic Techniques, Safety, and Marker-free Plants *573*
32.4 Regeneration of Transgene Plants *575*
32.4.1 Regeneration Procedures *575*
32.4.2 Compounds of Regeneration Media *576*
32.5 Plant Analysis: Identification and Characterization of Genetically Engineered Plants *577*
32.5.1 DNA and RNA Verification *577*
32.5.2 Protein Analysis *579*
32.5.3 Genetic and Molecular Maps *579*
32.5.4 Stability of Transgene Plants *580*
Further Reading *581*

33 Biocatalysis in the Chemical Industry *583*
B. Hauer, M. Breuer
33.1 Introduction *583*
33.2 Bioconversion/Enzymatic Procedures *590*
33.3 Development of an Enzyme for the Industrial Biocatalysis *593*
33.3.1 Identification of Novel Biocatalysts *593*
33.3.2 Improvement of Biocatalysts *594*
33.3.3 Production of Biocatalysts *596*
33.3.4 Outlook *596*
33.3.5 Case Example 1: Screening for New Nitrilases *597*
33.3.6 Case Example 2: Use of Known Enzymes for New Reactions: Lipases for the Production of Optically Active Amines and Alcohols *598*
33.3.7 Case Example 3: Enzyme Optimization with Rational and Evolutive Methods *600*
33.4 Fermentative Procedures *601*
33.4.1 Improvement of Fermentation Processes *601*
33.4.2 Classical Strain Optimization *602*
33.4.3 Metabolic Engineering *603*
33.4.4 Case Example 4: Production of Glutamine Acid with *Corynebacterium glutamicum* *604*
33.4.4.1 Molecular Mechanism of Glutamate Overproduction *605*
33.4.5 Case Example 5: Production of Lysine with *Corynebacterium glutamicum* *606*
33.4.5.1 Molecular Mechanism of Leucine Biosynthesis *607*
33.4.5.2 Deregulation of the Key Enzyme Aspartate Kinase *608*
33.4.6 Genomic Research and Functional Genomics *609*
33.4.7 Case Example 6: Fermentative Penicillin Production *610*

33.4.8 Case Example 7: Vitamin B2 Production *610*
33.4.8.1 Riboflavin Biosynthesis *611*
33.4.8.2 Classical Strain Development *611*
Further Reading *612*

Part IV Biotechnology in Industry

34 Industrial Application (Biotech Industry, Markets and Opportunities) *615*
J. Schüler
34.1 Historical Overview and Definitions of Concepts *615*
34.2 Areas of Industrial Application of Molecular Biotechnology *617*
34.2.1 Red Biotechnology *617*
34.2.1.1 Biopharmaceutical Drug Development *617*
34.2.1.2 Drug Delivery *620*
34.2.1.3 Cell and Gene Therapy *621*
34.2.1.4 Tissue Engineering and Regenerative Medicine *622*
34.2.1.5 Pharmacogenomics, Personalized Medicine, and System Biology *623*
34.2.1.6 Systems Biology *624*
34.2.1.7 Molecular Diagnostics *624*
34.2.2 Green Biotechnology *625*
34.2.2.1 Transgenic Plants *626*
34.2.2.2 Genomic Approaches in Green Biotechnology *626*
34.2.2.3 Novel Food and Functional Food *627*
34.2.2.4 Livestock Breeding *627*
34.2.3 Grey/White Biotechnology *627*
34.2.3.1 Technical Enzymes *627*
34.2.3.2 The Environment *628*
34.3 The Status Quo of the Biotech Industry Worldwide *628*
34.3.1 Global Overview *628*
34.3.2 USA *629*
34.3.3 Europe *629*
Further Reading *629*

35 Patents in the Pharmaceutical Biotechnology Industry: Legal and Ethical Issues *631*
David B. Resnik
35.1 Patent Law *631*
35.1.1 What is a Patent? *631*
35.1.2 How Does One Obtain a Patent? *633*
35.1.3 What is the Proper Subject Matter for a Patent? *634*
35.1.4 Types of Patents in Pharmaceutical Biotechnology *635*
35.1.5 Patent Infringement *635*
35.1.6 International Patent Law *636*

35.2 Ethical and Policy Issues in Biotechnology Patents 637
35.2.1 No Patents on Nature 637
35.2.2 Threats to Human Dignity 638
35.2.3 Access to Technology 640
35.2.4 Benefit Sharing 642
35.3 Conclusion 644
Further Reading 644

36 Drug Approval in the European Union and United States 647
Gary Walsh
36.1 Introduction 647
36.2 Regulation within the European Union 648
36.2.1 The EU Regulatory Framework 648
36.2.2 The EMEA 649
36.2.3 New Drug Approval Routes 650
36.2.3.1 The Centralized Procedure 650
36.2.3.2 Mutual Recognition 653
36.3 Regulation in the USA 653
36.3.1 CDER and CBER 654
36.3.2 The Approvals Procedure 655
36.4 International Regulatory Harmonization 657
Further Reading 658

37 The Emergence of a Biotechnology Industry 659
C. Kremoser
Further Reading 669

38 The 101 of Founding a Biotech Company 671
C. Kremoser
38.1 The First Steps Towards Your Own Company 671
38.2 Employees: Recruitment, Remuneration, Participation 677

39 Marketing 683
C. Kremoser
39.1 Introduction 683
39.2 What Types of Deals are Possible? 685
39.2.1 What Milestone or License Fees Are Effectively Paid in a Biotech/Pharma Cooperation? 685
39.3 Public Relations (PR) and Investor Relations (IR) in Biotech Companies 687
Further Reading 688

Glossary 689
M. Wink

Subject Index 733